Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant

Dent Neuroscience Research Center

Status and phase: Withdrawn; Phase 2

Conditions: Secondary Stroke Prevention; Clopidogrel Resistance

Treatments: Drug: Primidone

Study type: Interventional

Funder types: Other

Identifiers

NCT02008123

434350-2

Details and patient eligibility

About

The purpose of this study is to determine whether adding primidone will improve the metabolism of clopidogrel thereby increasing metabolite levels within the blood stream and platelet response to clopidogrel in patients who were previously found to lack adequate response to clopidogrel. This information could help overcome clopidogrel resistance in patients who are at risk for stroke or transient ischemic attack (TIA).

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females aged 18 - 90 years who are clopidogrel resistant as determined by whole blood aggregometry
• Patients with a low risk of new cerebrovascular ischemic events as indicated by an Essen Stroke Risk Score of less than three

Exclusion criteria

• Any history of allergy or intolerance to either Plavix or clopidogrel
• Any history of allergy or intolerance to either Mysoline or primidone
• Any clinically significant abnormalities in complete blood count as determined by the investigator
• Use of any acute medications within the last two weeks or initiation of any non-study medications during the study period that would effect CYP enzymes or platelet function
• Use of tobacco products from 2 weeks prior to enrollment in the study and throughout the duration of the study
• Any planned surgical procedures during the study or 5 days after the study has ended
• History of alcoholism or alcohol abuse
• Participants who have had any alcohol consumption within 24 hours of a blood draw
• Previous stroke in past 3 months
• Participants who are or are planning to become pregnant
• Participants who of reproductive potential must agree to use a method of contraception for the duration of the study as well as 4 weeks after participation is complete
• Change in any medications that could affect liver enzymes or platelet aggregation throughout the study
• Compliance less than 80 % based on pill counts on two different study visits

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Primidone

Experimental group

Description:

Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.

Treatment:

Drug: Primidone